Schedule 13G ownership disclosure
Corvus Pharmaceuticals Inc
Security class unavailable · CUSIP: 221015100
Event date: 2024-05-02
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 17,050,384
- Percent of class
- 9.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-24-003432
- Form type
- SC 13G
- Filer
- Corvus Pharmaceuticals, Inc.
- CIK
- CIK 1626971
- Filed
- May 09, 2024
- Reporting period
- May 02, 2024
- Description
- Schedule 13G beneficial ownership